JNJ - Johnson & Johnson Advances Its Two Bladder Cancer Studies Releases Latest Data | Benzinga
On Sunday, Johnson & Johnson (NYSE:JNJ) ) released updated results from an open-label, multicenter, multi-cohort Phase 1 study of TAR-210 in patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.
TAR-210 is an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder.
These data were featured at the 2024 American Urological Association (AUA) Annual Meeting.
Results featured updated data from Cohort 1 (C1), patients with recurrent, Bacillus Calmette-Guérin (BCG)–unresponsive high-risk (HR) NMIBC (high-grade Ta/T1; papillary only) who refused or were ineligible for radical cystectomy and Cohort 3 (C3), patients with recurrent, intermediate-risk NMIBC (Ta/T1) low-grade papillary disease left in situ as tumor marker lesions.
Also Read: Johnson & Johnson Wants To Deal With Talc Lawsuit Overhang, Proposes $6.5B Settlement Package.
At the data cutoff of March 22, ...